BoostmybodyYou decide

For a closer look

Research Library

Read what researchers wanted to find out and what it means in everyday words. Open the details if you want to see how a study was done. The product pages have a shorter explanation.

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Showing research linked to Semaglutide.

Back to the short explanation

2 studies found

Research context

What happened after the initial weight loss?

Adults with obesity or overweight, without diabetes, who completed the initial phase.

What did they want to find out?

What happens to weight when the intervention continues or is replaced with placebo?

What did researchers observe?

Weight continued falling on average with continuation and rose after the placebo switch.

What does this mean for you?

Lost weight can return; the finding describes maintenance under trial conditions.

What we still do not know

These percentages start at week 20, not the original weight. They do not tell an individual what to do.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

JAMA · 2021

How it was studied

Double-blind randomized withdrawal trial; 20-week initial phase followed by a 48-week comparison.. 803 adults without diabetes, selected from 902 who entered the initial phase..

Study finding

From week 20, weight changed −7.9% with continuation and +6.9% after switching to placebo; both groups had lifestyle support.

Study limitations

Selected people who tolerated the initial phase. Gastrointestinal symptoms were common; this does not represent everyone starting treatment.

Who is behind the study?

Identified authors
Domenica Rubino, Niclas Abrahamsson, Melanie Davies, Dan Hesse, Frank L. Greenway, Camilla Jensen, Ildiko Lingvay, Ofri Mosenzon, Julio Rosenstock, Miguel A. Rubio, Gottfried Rudofsky, Sayeh Tadayon, Thomas A. Wadden, Dror Dicker
Funding and involvement
Novo Nordisk A/S; involved in design, analysis and manuscript preparation, with no declared publication veto.
Disclosed interests and verification limits
Authors disclosed Novo Nordisk employment, shares, fees or support. This is not independent confirmation of the manufacturer.

Terms explained

Randomized withdrawal
After an initial phase, chance decides who continues and who switches to placebo.
Placebo
An intervention without the active ingredient, used for comparison.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source
Research context

The heart result: who participated matters

People with existing cardiovascular disease, not randomly selected healthy visitors.

What did they want to find out?

Were further major cardiovascular events reduced compared with placebo?

What did researchers observe?

There were fewer events of the combined outcome with semaglutide.

What does this mean for you?

6.5% versus 8.0% means a 1.5-percentage-point difference in this population and period.

What we still do not know

A benefit is not universal protection or an absence of adverse effects.

Show study details

Original sources checked on 4 October 2026. AI-assisted editorial summaries, not a systematic review or an independent medical assessment.

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

The New England Journal of Medicine · 2023

How it was studied

Multicenter randomized, double-blind, placebo-controlled trial.. 17,604 adults aged 45 or older with existing cardiovascular disease and overweight/obesity, without diabetes..

Study finding

The combined cardiovascular outcome occurred in 6.5% versus 8.0% with placebo over roughly 40 months of follow-up.

Study limitations

Did not study people without existing cardiovascular disease. More discontinued for adverse events: 16.6% versus 8.2%; safety collection was targeted.

Who is behind the study?

Identified authors
A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt-Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tugce K. Oral, Marie M. Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan
Funding and involvement
Novo Nordisk; designed the protocol with the academic steering committee.
Disclosed interests and verification limits
The article lists Novo Nordisk affiliations. Individual disclosure forms were not reviewed.

Terms explained

Combined outcome
Groups cardiovascular death, nonfatal heart attack or nonfatal stroke.
Percentage points
Difference between two percentages, not a percentage of body-weight loss.

Read the source and its limitations. A reference does not automatically validate a commercial product.

Read the source